A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

Please provide your email address to receive an email when new articles are posted on . All men with BRCA2 mutations treated with olaparib monotherapy achieved at least a 50% decline in PSA. The study ...

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...

Treatment intensification with the androgen receptor inhibitor enzalutamide shows benefit in patients with biochemically recurrent prostate cancer. Enzalutamide used alone or in combination with ...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post ...

In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared with leuprolide alone.